

Cerebral venous outflow participates in perihematomal edema after spontaneous intracerebral hemorrhage

A cross-sectional study

Hao Feng, MD^{a,b,c,d}, Zhanqiang Jin, MD^e, Wen He, MD^e, Xingquan Zhao, MD^{a,b,c,d,*}

Abstract

Cerebrospinal venous anatomy and hemodynamics changes are associated with many central nervous system disorders.

The aim of this study was to detect whether perihematomal edema (PHE) after spontaneous intracerebral hemorrhage (sICH) is associated with cerebral venous outflow volume (CVFV) in the internal jugular veins and vertebral veins.

Newly diagnosed cases of sICH between April 2016 and March 2017 were enrolled and patients were grouped to the mean value of PHE according to previous study. On computed tomography, absolute PHE volume was calculated as the difference between total lesion volume and intracerebral hemorrhage (ICH) volume. Relative PHE volume was defined as absolute PHE volume divided by ICH volume. CVFV was determined by Doppler ultrasound. Patients were divided according to mean values of absolute PHE at 3 and 12 days, and relative PHE (rPHE) at 3 and 12 days.

Significant differences were observed in smoking, alcohol consumption, glycosylated hemoglobin (GHb), secondary intraventricular hemorrhage (sIVH), and CVFV in PHE at 72 hours. Only sIVH and CVFV were significantly different at 12 days in PHE. In rPHE, GHb and sIVH were significantly differed at 72 hours. No significant difference was observed at 12 days in rPHE. The multivariate analyses showed that CVFV was independently associated with late PHE (PHE at 12±3 days) but not with early PHE (PHE at 72 hours) and rPHE.

These results suggest that CVFV may be closely related to PHE after sICH.

Abbreviations: BMI = body mass index, CBF = cerebral blood flow, CT = computed tomography, CVFV = cerebral venous outflow volume, FV = flow volume, GCS = Glasgow Coma Scale, GHb = glycosylated hemoglobin, Hb = hemoglobin, HU = Hounsfield unit, ICA = internal carotid artery, ICH = intracerebral hemorrhage, ICP = intracranial pressure, IJV = internal jugular vein, PHE = perihematomal edema, rPHE = relative PHE, sICH = spontaneous intracerebral hemorrhage, sIVH = secondary intraventricular hemorrhage, TAMV = time-averaged mean velocity, VA = vertebral artery, VV = vertebral vein.

Keywords: cerebral venous outflow, perihematomal edema, spontaneous intracerebral hemorrhage

1. Introduction

Spontaneous intracerebral hemorrhage (sICH) is a serious cerebrovascular disease and is associated with a poor prognosis. The mortality and morbidity of sICH have been associated with

This study was supported by Beijing Municipal Science and Technology Commission (Z161100002616008).

^a Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, ^b China National Clinical Research Center for Neurological Diseases, ^c Center of Stroke, Beijing Institute for Brain Disorders, ^d Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, ^e Department of Ultrasound, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

^{*} Correspondence: Xingquan Zhao, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China (e-mail: zxq@vip.163.com).

Medicine (2018) 97:35(e12034)

Received: 22 January 2018 / Accepted: 1 August 2018 http://dx.doi.org/10.1097/MD.000000000012034 early hematoma expansion, reduction in cerebral perfusion pressure, and raised intracranial pressure (ICP).^[1,2] Intracerebral hemorrhage (ICH) not only lead to primary brain injury through the direct mass effect of the hematoma, but also to secondary brain injury resulting in the formation of perihematomal edema (PHE), which evolves over hours to days. PHE can further augment the mass effect of the hemorrhage.^[3] Nevertheless, whether or not PHE formation contributes to morbidity and mortality is still controversial. It is widely accepted that hematoma-induced neuronal damage is irreversible, while that from PHE is reversible, making PHE a potential therapeutic target.^[2]

There are several potential mechanisms underlying PHE after ICH. In the very early phase (i.e., over the first few hours), there is the development of hydrostatic pressure and clot retraction, and the serum diffuses from the hematoma into the surrounding cerebral tissue. The second phase (i.e., over the first few days) involves coagulation and thrombin. The third phase is related to erythrocyte lysis and hemoglobin (Hb) toxicity. Nevertheless, the predictors and prognostic significance of growth in cerebral edema after ICH are still controversial.^[4]

The internal jugular veins (IJVs) are the main ways of cerebral blood drainage. Duplex ultrasound is a simple method to measure venous blood flow in IJVs and vertebral veins (VVs).^[5,6] Several studies have found that cerebrospinal venous anatomy

Editor: Massimo Tusconi.

The authors declare that they have no conflict of interest.

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

and hemodynamics changes are associated with many central nervous system disorders including leukoaraiosis dementia, normal-pressure hydrocephalus, multiple sclerosis, and edema after stroke.^[7–10] Therefore, we hypothesized that venous blood flow in the IJVs and VVs participates in the mechanism of PHE after sICH. Hence, the aim of the present study was to detect whether PHE after sICH is associated with cerebral venous outflow volume (CVFV) in the IJVs and VVs.

2. Methods

2.1. Study design

This cross-sectional study was conducted at the Department of Neurology of Beijing Tiantan Hospital. This study has been approved by the Ethics Committee of Beijing Tiantan Hospital affiliated to the Capital Medical University of China, in compliance with the Declaration of Helsinki. Written informed consent study was obtained from all patients or their legal representative.

2.2. Patients

Between April 2016 and March 2017, newly diagnosed sICH cases were prospectively enrolled. ICH was confirmed by computed tomography (CT) scan. The inclusion criteria were age between 18 and 80 years; patients diagnosed with supratentorial sICH; and time from the onset of the symptoms to the first CT scan was <24 hours. The exclusion criteria were deep coma [Glasgow Coma Scale (GCS) 3–5]; anticoagulant therapy, trauma, tumor, arteriovenous malformations, or subarachnoid hemorrhage; acute thrombolysis- or coagulopathy-caused ICH; systemic disease influencing venous hemodynamics (venous thrombosis, arteriovenous malformation, dural fistulas, massive right ventricular insufficiency, or pulmonary hypertension); or surgical intervention before the follow-up CT scan.

In order to investigate the relationship between CVFV and PHE, we classified the patients according to the mean value of the 72-hour absolute PHE (10.18 mL), 72-hour relative PHE (0.97), 12-day absolute PHE (13.38 mL), and 12-day relative PHE (1.14). Patients with PHE larger than the values presented above were grouped into the larger group and those with PHE smaller than the mean value were grouped in the smaller group.^[11]

2.3. Baseline data

Demographics including age, sex, and body mass index (BMI) (kg/m²) were recorded. Blood samples were collected from each patient the day of hospital admission for the measurement of white blood cell, platelets, Hb, creatinine, blood urea nitrogen, uric acid, blood glucose, international normalized ratio, activated partial thromboplastin time, glycosylated hemoglobin (GHb), and erythrocyte sedimentation. Clinical and neurological evaluations were performed, including first blood pressure measurement after onset, as well as history of smoking, hemorrhagic and ischemic stroke, diabetes mellitus, and hypertension. History of smoking was defined as currently smoking or past smoking (i.e., no smoking for the past 5 years). Arterial hypertension was defined as systolic blood pressure \geq 140 mm Hg and/or diastolic blood pressure \geq 90 mm Hg, or selfreported current treatment for arterial hypertension with antihypertensive medications. On the admission day, the patients were assessed for stroke severity, consciousness state, and the level of handicap according to the National Institutes of Health Stroke Scale^[12] and GCS.^[13]

2.4. Imaging

Diagnosis was determined by CT scanner (General Electric), with 512×512 matrix, FOV of 15 cm, and slice thickness of 9 or 10 mm (supratentorial) and 4.5 or 5 mm (infratentorial). Two neuroradiologists blindly and independently reviewed the CT scans, and hemorrhage with intraventricular extension was documented. Absolute PHE volume was calculated as the difference between total lesion volume and hematoma volume. Briefly, the examiner drew regions of interest by tracing the hyperdense area perimeter, representing the hematoma [Hounsfield unit (HU) range, 40-100 HU], and the hypodense region surrounding the hematoma, indicating PHE (range, 5-33 HU), in each slice throughout the lesion. Hematoma and total lesion volumes were calculated by multiplying the specific traced area by slice thickness and summing the results. PHE was measured by subtracting the hyperdense volume (hematoma) from the total lesion area (hyperdense + hypodense lesion area) (Fig. 1). Relative PHE was then calculated by dividing the absolute PHE by hematoma volume.^[14] When PHE was undetectable, PHE volume value of zero was assigned. Hematomas were classified as "deep" if they were located in the basal ganglia, thalamus, or internal capsule; all other hemorrhages were classified as "lobar."^[15]

2.5. Duplex ultrasound

Color-coded duplex ultrasound was performed in all subjects with a 7-MHz linear transducer (iU22; Philips, Best, The Netherlands). Briefly, subjects were in a head-straight, flat supine position after a 10-minute quiet rest. The vascular ultrasound radiologist was particularly experienced with venous disease and had performed approximately 7000 ultrasound investigations per year over the past few years. Each subject underwent an examination of the laterocervical area of the neck, exploring both the IJVs and VVs. Longitudinal supine scans of the IJVs were obtained from the distal part (J3) above the carotid bifurcation to the subclavian junction (J1), passing through the intermediate



Figure 1. Boundaries of the hematoma and perihematomal edema using predefined radiological criteria: hyperdensity for hematoma regions (red arrow) and hypodensity in perihematomal distribution for perihematomal edema (blue arrow).



Figure 2. Calculation of the cross-sectional lumen area of the internal jugular vein.

portion at the level of the cricoid cartilage (J2). The longitudinal diameters were measured at the levels of J2. Measurements of the cross-sectional area (CSA, mm²) of the IJVs were obtained in realtime at the same point (J2) (Fig. 2). The VV diameters were obtained in the sagittal plane (Fig. 3) and the cross-sectional area was calculated assuming a circular shape. Time-averaged mean velocity (TAMV) (Fig. 4) was measured using the built-in software (iU22; Philips).^[7] On the skin, we used a large amount of gel to assure good coupling of the transducer, reduce excessive pressure, and avoid changing the IJV shape and dimension.^[16] Venous outflow volume of IJVs and VVs was calculated from the TAMV and the CSA of the vessel (venous outflow volume= $CSA \times TAMV$). The total CVFV was then calculated by adding the IJVs volume and VVs volume.^[8]

The internal carotid arteries (ICAs) and vertebral arteries (VAs) were analyzed with the head rotated 20° to 30° to the opposite side and at least 2 cm distal of the carotid bifurcation. The intravascular flow volumes (FVs) of ICAs and VAs were calculated as the product



Figure 3. Calculation of the diameter of the W. VA = vertebral artery, W = vertebral vein.



Figure 4. Calculation of the time-averaged mean velocity (TAMV) of the internal jugular vein (left) and vertebral vein (right).

of TAMV and the CSA of the circular vessel according to the formula FV=TAMV×CSA=TAMV×[$(d/2)^2 \times \pi$] (where "d" represents for diameter of the blood vessel). The arterial global cerebral blood flow (CBF) volume was determined as the sum of the FVs of the ICA and the VA of both sides.^[17,18]

heterogeneous variables. These covariates were then included in a multivariate binary logistic regression with the threshold of significance set at P < .10. Statistical analyses were performed using SPSS (version 24.0). All analyses were 2 tailed, and significance level was determined as P < .05.

2.6. Statistical analysis

Continuous variables were presented as median (interquartile range) when they were not normally distributed and as mean \pm standard deviation when they were normally distributed (according to the Kolmogorov-Smirnov normality test). Univariate analysis was applied to identify variables associated with PHE. The continuous variables were analyzed using the independent Student *t* test, whereas the categorical variables were analyzed using the chi-square test. The Mann-Whitney *U* test was used to analyze independent groups in case of non-normally distributed or

3. Results

3.1. Patients

A total of 108 subjects with sICH were enrolled. Among them, 11 cases were excluded for secondary ICH, 25 for surgical treatment before the follow-up CT scan, 2 for incomplete Doppler ultrasound data, and 9 were discharged before the follow-up CT scan. Finally, 61 patients were included for analysis (Fig. 5). Age, sex, and BMI were comparable between groups at the 2 time points (Table 1). Significant differences were observed in





			PHE (72 h)		PHE (12	± 3 day)		rPHE	(72 h)		rPHE (12	(±± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ±	
Apply (mem_±0) 5 ± 11 114 1124		Total (n=61)	Larger $(n = 23)$	Small (n = 38)	Ρ	Larger $(n=21)$	Small (n = 40)	Ρ	Larger $(n=23)$	Small $(n = 38)$	Ρ	Larger (n = 20)	Small $(n = 41)$	Ρ
	yr, mean±SD	55±11	54 ± 11	55 土 11	.845	55 土 11	55 土 11	.984	55 ± 11	54 ± 11	.778	56±11	54 ± 11	.402
Fermion 18 (25) 7 (30,4) 11 (26) 7 (30,4) 11 (26) 7 (30,4) 12 (31) 12 (31) 12 (31) 12 (31) 12 (31) 12 (31) 12 (31) 12 (31) 12 (31) 12 (31) 12 (31) 12 (31) 12 (31) 13 (31)	'ale, n (%)	43 (70.5)	16 (69.6)	27 (71.1)	.902	15 (71.4)	28 (70.0)	706.	17 (73.9)	26 (68.4)	.649	14(70.0)	19(46.3)	.953
BM, mediar (D) 558 ± 42 568 ± 43 537 ± 47 537 ± 30 174 ± 32 101 ± 77 105 ± 20 117 ± 36 220 117 ± 36 232 117 ± 36 $237+3$ 172 ± 30 200 127 ± 30 120 117 ± 36 1232 $123+30$ 120 $121+30$ $121+30$ $121+30$ $121+30$ $121+30$ $121+30$ $121+30$ $121-30$ $121+3$	smale, n (%)	18 (29.5)	7 (30.4)	11 (28.9)		6 (28.6)	12 (30.0)		6 (26.1)	12 (31.6)		6(30.0)	12(29.3)	
Witss, meane (in) $4,2-6$ $7,2-6$ $3(1-7)$ 056 $7,2-6$ $4(1-6)$ $14(1-5)$ $12(1-5)$	MI, mean±SD 5	25.8±4.2	26.0 ± 3.4	25.7 ± 4.7	.831	25.8 ± 3.8	25.8 ± 4.4	.976	27.0 ± 4.2	25.1 ± 4.1	.083	26.3 ± 4.0	25.6 ± 4.3	.556
GCS media (0) 14 (13-15) 14 (14-15) 15 (13-15) 16 (14-15) 15 (14-15) 14 (13-15) 14 (13-15) 14 (13-15) 14 (13-15) 14 (13-15) 14 (13-15) 15 (14-15) 15 (14-15) 15 (14-15) 16 (14-15) 16 (14-15) 16 (13-2) 200 15 (14-15) 14 (13-15) 200 15 (14-15) 14 (13-15) 200 <	HSS, median (IQR)	4 (2–8)	7 (3–9)	3 (1–7)	.056	7 (2–8)	4 (1–8)	.198	6 (2–9)	4 (1–8)	.174	5(2-8)	4(19)	.758
BBP, mm Hg, memar SD 174 ± 32 166 ± 34 177 ± 30 166 ± 34 177 ± 36 166 ± 34 171 ± 36 166 ± 34 176 ± 36 220 232 176 ± 36 220 232 116 ± 30 106 ± 37 106 ± 20 232 100 120 120 120 120 $106+3$ 56 100 $116+30$ 120 100 $116+30$ 210 2	CS, median (IQR)	14 (13–15)	14 (14–15)	15 (13–15)	.848	14 (13-15)	15 (14–15)	.200	15 (14–15)	14 (13–15)	.533	14(13-15)	15(14–15)	.735
BP, mm Hg, mean±SD 104±18 101±17 105±20 407 101±16 105±20 34 102±17 106±20 324 Hstry of Mp, n(%) 5 (65.2) 2 (91.3) 3 (16.3) 5.06 19 (90.5) 33 (7.3) 100±17 106±20 32 (4.2) 100 Hstry of Mp, n(%) 5 (62.2) 2 (91.3) 3 (16.3) 5 (6.3) 0 007 9 (3.3) 7 (30.4) 12 (8.7) 7 (18.4) 10.00 Hstry of Mp, n(%) 5 (82.7) 7 (30.4) 5 (8.5) 0 007 9 (3.2) 2 (17.7) 7 (18.4) 10.00 Hstry of Mp, n(%) 3 (55.7) 7 (30.4) 5 (6.5) 0 007 9 (4.2.) 2 (17.7) 7 (18.4) 10.00 How (n) 3 (55.7) 7 (30.4) 2 (6.5) 0 007 9 (4.2.) 2 (6.7.2) 2 (6.7.2) 2 (7.1) 7 (18.4) 10.00 Mondin, (%) 5 (5.6 -5.9) 5 (6.5 %) 0 007 9 (4.2.9) 5 (6.5.2.5) 2 (7.7) 7 (3.4.7.2) 3 (7.3) 2 (7.1) 2 (7.2) 2 (7.2) 2 (3P, mm Hg, mean±SD	174 ± 32	166 ± 34	179 ± 30	.119	168 ± 24	177 ± 36	.328	167 ± 35	178 ± 30	.200	167 ± 27	178 ± 34	.216
History of hypertension, (6) 22 (65.2) 2 (91.3) 31 (91.6) 53 (82.5) 642 (91.3) 31 (91.6) 37 (91.6) 3	BP, mm Hg, mean±SD	104 ± 18	101 ± 17	105 ± 20	.407	101 ± 16	105 ± 20	.444	102 ± 17	106 ± 20	.324	97 ± 16	107 ± 19	.062
History of DM, n (%) 10 (16,4) 6 (26,1) 4 (10,5) 217 6 (28,6) 4 (10,0) 134 7 (30,4) 3 (79) 205 1450 (16,4) (12,6) 120 1450 (16,4) (12,1) 120 1450 (16,1) (12,1) 120 1450 (10,1) (13,1) 2 (12,1) 120 1450 (10,1) (13,1) 2 (12,1) 120 1450 (10,1) (13,1) 2 (12,1) 120 1450 (10,1) (13,1) 2 (12,1) 120 1450 (10,1) (13,1) 2 (12,1) 120 1450 (10,1) 13 (12,1) 13 (12,1) 120 1450 (10,1) 13 (12,2) 120 1450 (10,1) 13 (12,2) 120 1450 (10,1) 13 (12,2) 120 1450 (10,1) 13 (12,2) 120 1450 (10,1) 13 (12,2) 120 1450 (10,1) 13 (12,2) 13 (12,2) 13 (12,2) 13 (12,2) 13 (12,2) 13 (12,2) 13 (12,2) 13 (12,2) 13 (12,2) 13 (12,2) 13 (12,2) 13 (12,1) 13 (12,2) 13 (12,1) 13 (12,2) 13 (12,1) 13 (12,1) 13 (12,2) 13 (12,1) 13	istory of hypertension, n (%)	52 (85.2)	21 (91.3)	31 (81.6)	.506	19 (90.5)	33 (82.5)	.649	20 (87.0)	32 (84.2)	1.000	17(85.0)	35(85.4)	1.000
History of hyperflipterma, n (%) 5 (8.2) 3 (13.0) 2 (5.3) 5 (5.4) 2 (9.5) 3 (7.5) 1 000 4 (17.4) 1 (2.6) 1 200 Strewing, n (%) 3 (5.7) 5 (21.7) 7 (18.4) 1 000 5 (23.3) 2 (7.5) 3 (60.5) 3 (7.5) 1 (12.6) 1 (2.6) 1 (7.4) 1 (2.6) 3 (7.5) 3 (60.5)	story of DM, n (%)	10 (16.4)	6 (26.1)	4 (10.5)	.217	6 (28.6)	4 (10.0)	.134	7 (30.4)	3 (7.9)	.051	6(30.0)	4(9.8)	.102
Hstory of C00, n (%) 12 (19.7) 5 (21.7) 7 (18.4) 1.000 5 (23.8) 7 (17.5) 803 5 (21.7) 7 (18.4) 1.000 Smoking, n (%) 23 (55.5) 7 (30.4) 25 (65.8) 0.07 9 (42.9) 23 (57.5) 227 10 (43.5) 22 (65.7) 227 Smoking, n (%) 35 (52.5) 7 (30.4) 25 (65.8) 0.07 9 (42.9) 23 (57.5) 227 11 (47.20) 23 (67.5) 227 11 (47.20) 23 (67.5) 227 11 (47.20) 23 (60.5) 33 3 33 3 K5, median (0R) 55 (52-5.6) 58 (63.4-5.0) 116 (6-20) 116 (6-20) 12 (47.2) 23 (60.5) 33 3 33 3 33 3 33 3 33 3 33 3 33 3 33 3 33 3 34 (17.25) 23 (60.5) 37 (47.5) 23 (60.5) 33 3 33 3 33 3 33 3 33 3 33 3 33 3 33 3 34 (17.25) 36 (60.5) 32 (60.5) 32 (7 (4.25.5) 30 6 37 (4.25.5) 36 (6.25.5) 32 (7 (4.25.5) 37 (4.25.5)	istory of hyperlipidemia, n (%)	5 (8.2)	3 (13.0)	2 (5.3)	.554	2 (9.5)	3 (7.5)	1.000	4 (17.4)	1 (2.6)	.120	3(15.0)	2(4.9)	.392
Smoking, n (%) 32 (52.5) 7 (30.4) 25 (65.8) 007 9 (42.9) 23 (57.5) 27 10 (43.5) 22 (57.9) 275 Atomol, n (%) 34 (55.7) 53 (33.1) 25 (65.8) 042 11 (47.2) 337 23 (60.5) 333 Geb (%), median (0R) 13 (6-24) 19 (6-20) 125 (62.5) 006 55 (52.5.6) 236 (0.9) 137 (17.22) 870 Gib (%), median (0R) 53 (52-5.6) 53 (52-5.6) 53 (6.2-5.9) 14 (6-27) 876 14 (6-27) 870 Gib (%) 937 ($4,7-6.80$ 173 ($4,19-6.80$ 4.76 ($4,19-6.30$ 4.22 ($4,17-2.3$) 870 14 ($7-22$) 870 MR, median (0R) 487 ($4,37-5.72$) 537 ($4,17-6.80$ 4.78 ($4,19-6.30$) 4.27 ($4,19-6.30$) 4.27 ($4,19-6.30$) 4.77 ($4,35-6.64$) 221 ($5.75-6.61$) 221 ($5.75-6.61$) 221 ($5.75-6.61$) 221 ($5.75-6.61$) 221 ($5.72-6.61$) 221 ($5.72-6.61$) 221 ($7.25-6.61$) 221 ($7.25-6.61$) 221 ($7.25-6.61$) 221 ($7.25-6.61$) 221 (7	istory of CVD, n (%)	12 (19.7)	5 (21.7)	7 (18.4)	1.000	5 (23.8)	7 (17.5)	.803	5 (21.7)	7 (18.4)	1.000	5 (25.0)	7 (17.1)	.698
Atonol, (%) $34(557)$ $9(39.1)$ $25(65.9)$ 042 $9(42.9)$ $25(62.5)$ $23(60.5)$ 333 Ex. much, median (0R) $13(6-24)$ $19(6-20)$ $11(6-20)$ 1126 $8(6-28)$ $14(6-23)$ 826 $11(7-22)$ 870 Git, much/i, median (0R) $55(52-59)$ $58(54-6.1)$ $5.4(52-56)$ 006 $55(52-58)$ 456 $58(54-6.5)$ $54(52-56)$ 006 $006(090-102)$ 817 $(335-564)$ $23(43-563)$ $23(43-563)$ $23(43-563)$ $23(43-563)$ $23(43-563)$ $23(43-563)$ $23(43-563)$ $23(43-563)$ $23(43-563)$ $23(43-563)$ $23(43-563)$ $23(43-563)$ $23(43-563)$ $23(60-102)$ $237(42-630)$ $23(74-73)$ $237(42-63)$ $23(60-102)$ $237(42-63)$ $23(60-102)$ $237(42-63)$ $23(60-102)$ $237(42-63)$ $23(60-2)$ $23(60-2)$ $23(60-2)$ $23(60-2)$ $23(60-2)$ $23(60-2)$ $23(60-2)$ $23(60-2)$ $23(60-2)$ $23(60-2)$ $23(60-2)$ $23(60-2)$ $23(60-2)$ $23(60-2)$ <	moking, n (%)	32 (52.5)	7 (30.4)	25 (65.8)	.007	9 (42.9)	23 (57.5)	.277	10 (43.5)	22 (57.9)	.275	9 (45.0)	23 (56.1)	.238
ES, mu/h, median (0P) 13 (6–24) 19 (8–28) 11 (6–20) .125 8 (6–28) 14 (6–23) 826 12 (5–28) 14 (7–22) 870 (64) (64) median (0P) 55 (52–56) 53 (54–56) 53 (54–56) 54 (52–56) 206 (64) median (0P) 55 (52–56) 53 (54–56) 53 (55	'cohol, n (%)	34 (55.7)	9 (39.1)	25 (65.8)	.042	9 (42.9)	25 (62.5)	.232	11 (47.8)	23 (60.5)	.333	9 (45.0)	25 (61.0)	.238
Gth (%), median (0R) 55 (5,2-5;0) 58 (5,4-6;1) 5.4 (5,2-5;6) 0.08 55 (5,4-5;0) 55 (5,4-6;5) 5.4 (5,2-5;6) 0.06 Ru, mond, median (0R) 487 (4,37-572) 537 (4,47-668) 4.78 (4,33-5,52) 0.09 4.75 (4,39-6,38) 4.27 (4,35-5,64) 2.21 5 NR, median (0R) 0.96 (0.91-10.0)	3, mm/h, median (IQR)	13 (6–24)	19 (8–28)	11 (6–20)	.125	8 (6–28)	14 (6–23)	.826	12 (5–28)	14 (7–22)	.870	8 (5–28)	16 (7–23)	.406
Glu, mmol/L, median (0R) 4.87 ($4.37-5.72$) 5.37 ($4.47-6.68$) 4.78 ($4.33-5.52$) 0.90 4.75 ($4.19-6.38$) 4.92 ($4.38-5.62$) 3.77 ($4.35-5.64$) 221 5 NR, median (0R) 0.96 ($0.91-1.01$) 0.96 ($0.91-1.00$) 693 0.96 ($0.93-1.07$) 0.96 ($0.91-1.01$) 0.96 ($0.91-1.01$) 0.96 ($0.91-1.01$) 0.96 ($0.91-1.01$) 0.96 ($0.91-1.01$) 0.96 ($0.93-1.07$) 0.96 ($0.90-1.02$) 3.77 ($4.35-5.64$) 221 26.3 ± 3.3 257.0 ± 67 3.17 25.8 ± 3.7 25.3 ± 3.3 257.0 ± 67 3.17 25.9 ± 2.6 26.4 ± 3.7 5.55 UA, µmol/L, mean ±SD 50.0 ± 1.7 25.5 ± 3.1 3.10 250.0 ± 7.1 25.9 ± 2.6 26.4 ± 3.7 5.55 UA, µmol/L, mean ±SD 50.0 ± 1.7 $52.51.7 \pm 7.34$ 3.10 $250.0\pm3.12.5$ 3.05 3.77 ± 72.2 5.74 3.77 ± 70.7 277 UA, µmol/L, mean ±SD 50.0 ± 1.7 52.5 ± 3.16 5.5 ± 1.17 4.9 ± 1.7 5.67 ± 1.26 $26.1+12.01$ 5.61 26.113 5.0 ± 1.9 5.0 ± 1.12 5.27	Hb (%), median (IQR)	5.5 (5.2–5.9)	5.8 (5.4–6.1)	5.4 (5.2–5.6)	.008	5.5 (5.4–5.9)	5.5 (5.2–5.8)	.455	5.8 (5.4–6.5)	5.4 (5.2–5.6)	.006	5.4 (5.3–5.9)	5.5 (5.2–5.8)	.771
NR, median (0R) $0.96 (0.91-1.01)$ $0.96 (0.91-1.06)$ $0.96 (0.91-1.01)$ $0.96 (0.91-1.01)$ $0.96 (0.91-1.06)$ $0.96 (0.91-1.02)$ 817 $0.96 (0.93-0.99)$ 421 $0.96 (0.93-0.99)$ $0.96 (0.93-0.99)$ $0.96 (0.90-1.02)$ 817 $0.96 (0.91-1.01)$ $0.96 (0.91-1.06)$ $0.96 (0.91-1.06)$ $0.96 (0.91-1.01)$ $0.96 (0.91-1.01)$ $0.96 (0.91-1.02)$ 0.817 $0.96 (0.91-1.02)$ 0.817 $0.95 (0.91-1.02)$ 0.817 ± 12.1 $0.95 (0.91-1.02)$ 0.817 ± 12.1 $0.95 (0.91-1.02)$ 0.817 ± 12.1 0.919 APTT, s, mean ± SD $2.45.0 \pm 71.13$ $2.57.1 \pm 72.3$ 2.93 ± 13.5 $3.21 \pm 26.0 \pm 3.71 \pm 70.7$ 2.722 0.919 0.910 ± 12.01 0.916 ± 12.1 1.611 BUN mmolL, mean ± SD 5.0 ± 1.3 4.18 63.0 ± 14.1 5.93 ± 13.5 3.21 ± 20.2 2.937 ± 12.1 1.61 BUN mmolL, mean ± SD 5.0 ± 1.17 6.22 ± 1.17 4.9 ± 1.7 $60.7 \pm 3.21 \pm 50.2$ 2.93 ± 16.6 2.61 ± 1.9 2.915 ± 3.04 9.78 ± 3.08 4.45 PUT ($\times 10^{0}$ L), mean ± SD 2.14 ± 15 1.21	lu, mmo//L, median (IQR) 4	1.87 (4.37–5.72)	5.37 (4.47–6.68)	4.78 (4.33–5.52)	060.	4.75 (4.19–6.38)	4.92 (4.38–5.62)	.816	5.29 (4.42–6.38)	4.77 (4.35–5.64)	.221	5.49 (4.53-6.44)	4.78 (4.34–5.40)	.089
APTL, s, mean ± SD 26.3 ± 3.3 25.8 ± 3.7 26.5 ± 3.1 431 25.4 ± 2.7 26.7 ± 3.6 151 25.9 ± 2.6 26.4 ± 3.7 535 UA, µmol/L, mean ± SD 245.0 ± 71.3 257.0 ± 67.8 237.7 ± 73.4 310 250.0 ± 71.0 242.3 ± 72.3 694 257.1 ± 72.0 237.1 ± 70.7 272 UA, µmol/L, mean ± SD 60.0 ± 13.7 62.4 ± 14.6 59.5 ± 13.3 418 63.0 ± 14.1 59.3 ± 1.7 4.9 ± 1.7 247.2 27.1 ± 72.0 237.1 ± 70.7 272 UN, µmol/L, mean ± SD $50.0\pm1.3.7$ 62.4 ± 14.6 59.5 ± 13.3 418 63.0 ± 14.1 59.3 ± 1.7 4.9 ± 1.7 364 $50.\pm1.3$ 5.0 ± 19 9.16 WBC ($\times 10^9/L$), mean ± SD 9.55 ± 3.05 9.57 ± 2.92 9.52 ± 3.165 9.65 3.662 26.13 3.445 VBC ($\times 10^9/L$), mean ± SD 144 ± 17 144 ± 16 143 ± 17 146 ± 2.0 144 ± 15 7.74 143 ± 17 146 ± 2.1 144 ± 15 7.74 146 ± 2.1 146 ± 2.6 144 ± 15 7.74	IR, median (IQR) C).96 (0.91–1.01)	0.96 (0.91-1.06)	0.96 (0.91–1.00)	.693	0.96 (0.93-1.07)	0.96 (0.90-0.99)	.421	0.96 (0.93-0.98)	0.96 (0.90–1.02)	.817	0.96 (0.93-1.01)	0.96 (0.91–1.01)	.841
UN, $\mu mo(l, mean\pm SD = 245.0\pm71.3 = 257.0\pm67.8 = 237.7\pm73.4 = .310 = 250.0\pm77.10 = 242.3\pm72.3 = .694 = 257.1\pm7.01 = .272 = .27$	РП, s, mean±SD	26.3 ± 3.3	25.8 ± 3.7	26.5 ± 3.1	.431	25.4 ± 2.7	26.7 ± 3.6	.151	25.9 ± 2.6	26.4 ± 3.7	.535	26.1 ± 2.6	26.3 ± 3.6	.813
Cr, μ mol/r, mean \pm SD 60.0 \pm 13.7 62.4 \pm 14.6 59.5 \pm 13.3 .418 63.0 \pm 14.1 59.3 \pm 13.5 .321 63.8 \pm 15.8 58.7 \pm 12.1 .161 BUN, mmol/r, mean \pm SD 5.0 \pm 1.7 5.2 \pm 1.7 4.9 \pm 1.7 .607 5.3 \pm 1.7 4.9 \pm 1.7 .364 5.0 \pm 1.3 5.0 \pm 1.9 .919 WBC (× 10 ⁹ /L), mean \pm SD 9.55 \pm 3.05 9.57 \pm 2.92 9.52 \pm 3.16 .955 9.62 \pm 3.08 9.50 \pm 3.07 .885 9.15 \pm 3.04 9.78 \pm 3.08 .445 WBC (× 10 ⁹ /L), mean \pm SD 231 \pm 60 231 \pm 54 231 \pm 65 .955 .965 \pm 4.20 144 \pm 15 .774 143 \pm 17 146 \pm 17 .553 Hb, QL, mean \pm SD 144 \pm 17 143 \pm 17 143 \pm 17 146 \pm 20 144 \pm 15 .774 143 \pm 17 146 \pm 17 .553 Baseline hematoma 8.42 (5.84 - 14.01) 8.02 (5.53 - 12.37) .766 7.65 (5.64 - 12.54) 9.37 (5.79 - 15.08) .46 (6.71 - 12.01) .288 7.1 volume, mL, median (IQR) 8.42 (5.84 - 14.01) 8.02 (5.55 - 12.37) .766 7.65 (5.64 -	A, μmol/L, mean±SD 24	45.0 ± 71.3	257.0 ± 67.8	237.7 ± 73.4	.310	250.0 ± 71.0	242.3 ± 72.3	.694	257.1 ± 72.0	237.1 ± 70.7	.272	225.9 ± 68.2	239.6 ± 73.0	.406
BUN mmolL, mean \pm D 5.0 ±1.7 5.2 ±1.7 4.9 ±1.7 5.0 5.3 ±1.7 4.9 ±1.7 3.64 5.0 ±1.3 5.0 ±1.9 3.919 WBC (×10 ⁹ /L), mean \pm SD 9.55 ±3.05 9.57 ±2.92 9.52 ±3.16 3.55 9.65 ±3.08 9.50 ±3.07 8.85 9.15 ±3.04 9.78 ±3.08 3.45 PLT (×10 ⁹ /L), mean \pm SD 2.31 \pm 60 2.31 \pm 54 2.912 0.52 ±3.16 3.55 9.62 \pm 3.08 2.50 \pm 62 2.32 \pm 65 3.95 10, g/L, mean \pm SD 144 ±17 143 \pm 17 143 \pm 17 146 \pm 17 3.53 Baseline hematoma 8.42 (5.84 - 14.01) 8.02 (5.95 - 18.45) 8.60 (5.53 - 12.37) 7.66 7.65 (5.64 - 12.54) 9.37 (5.79 - 15.08) 7.71 4.13 \pm 17 146 \pm 17 5.53 Baseline hematoma 8.42 (5.84 - 14.01) 8.02 (5.95 - 18.45) 8.60 (5.53 - 12.37) 7.66 7.65 (5.64 - 12.54) 9.37 (5.79 - 15.08) 7.2 18.21 (4.73 - 21.60) 8.46 (6.71 - 12.01) 2.88 7.00 ubume, mL, median (IQR) 4.0 (RR) 4.9 (8.53 - 12.37) 7.66 7.65 (5.64 - 12.54) 9.37 (5.79 - 15.08) 7.2 18.21 (4.73 - 21.60) 8.46 (6.71 - 12.01) 2.88 7.00 ubume, mL, median (IQR) 4.0 (RR) 4.9 (8.53 - 12.37) 7.66 7.65 (5.64 - 12.54) 9.37 (5.79 - 15.08) 7.2 18.21 (4.73 - 21.60) 8.46 (6.71 - 12.01) 2.88 7.00 ubume, mL, median (IQR) 4.0 (RR) 4.9	r, μmol/L, mean±SD €	30.0 ± 13.7	62.4 ± 14.6	59.5 ± 13.3	.418	63.0 ± 14.1	59.3 ± 13.5	.321	63.8 ± 15.8	58.7 ± 12.1	.161	63.1 ± 14.6	59.4 ± 13.3	.333
WBC (×10 ⁹ /L), mean±SD 9.55±3.05 9.57±2.92 9.52±3.16 .955 9.62±3.08 9.50±3.07 .885 9.15±3.04 9.78±3.08 .445 PLT (×10 ⁹ /L), mean±SD 231±60 231±54 2.31±65 .999 223±59 2.36±62 .420 231±52 232±65 .965 Hb, g/L, mean±SD 144±17 143±17 146±17 .553 Baseline hematoma 8.42 (5.84–14.01) 8.02 (5.95–18.45) 8.60 (5.53–12.37) .766 7.65 (5.64–12.54) 9.37 (5.79–15.08) .721 8.21 (4.73–21.60) 8.46 (6.71–12.01) .288 7. volume, mL, median (IQR) 49 (80.3) 18 (78.3) 31 (81.6) 1.000 18 (85.7) 31 (77.5) .669 19 (82.6) 30 (78.9) .987 Location Perter (78) 27 (8.4) .018 3.14.33 19 (47.5) .669 19 (82.6) 30 (78.9) .987 Location 7.2 (8.4) .018 3.14.33 19 (47.5) .669 19 (82.6) 30 (78.9) .987 Location 7.2 (8.4) .018 3.14.33 19 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 19 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 19 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 19 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 19 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 19 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 19 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 19 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 19 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) .010 0.018 (47.4) .018 3.14.33 10 (47.5) .010	JN, mmol/L, mean ±SD	5.0 ± 1.7	5.2 ± 1.7	4.9 ± 1.7	.607	5.3 ± 1.7	4.9 ± 1.7	.364	5.0 ± 1.3	5.0 ± 1.9	.919	5.5 ± 1.8	4.8 ± 1.7	.166
PLT (×10 ³ L), mean ±SD 231 ±60 231 ±54 231 ±65 .999 223 ±59 236 ±62 .420 231 ±52 232 ±65 .965 Hb, g/L, mean ±SD 144 ±17 143 ±19 156 ±16 .543 146 ±20 144 ±15 .774 143 ±17 146 ±17 .553 Baseline hematoma 8.42 (5.84 − 14.01) 8.02 (5.95 − 18.45) 8.60 (5.53 − 12.37) .766 7.65 (5.64 − 12.54) 9.37 (5.79 − 15.08) .721 8.21 (4.73 − 21.60) 8.46 (6.71 − 12.01) .288 7. volume, mL, median (IQR) Location (%) 49 (80.3) 18 (78.3) 31 (81.6) 1.000 18 (85.7) 31 (77.5) .669 19 (82.6) 30 (78.9) .987 Location %) 12 (19.7) 5 (21.7) 7 (18.4) .018 3.14.33 19 (47.5) 0.10 4.17.40 18 (47.4) .018 3.14.33 19 (47.5) 0.10 4.17.40 18 (47.4) .018 3.14.33 19 (47.5) 0.10 4.17.40 18 (47.4) .018	'BC (×10 ⁹ /L), mean±SD 5	9.55 ± 3.05	9.57 ± 2.92	9.52 ± 3.16	.955	9.62 ± 3.08	9.50 ± 3.07	.885	9.15 ± 3.04	9.78 ± 3.08	.445	9.34 ± 3.66	9.65 ± 2.74	.715
Hb, g/L, mean±SD 144±17 143±19 156±16 .543 146±20 144±15 .774 143±17 146±17 .553 Baseline hematoma 8.42 (5.84−14.01) 8.02 (5.95−18.45) 8.60 (5.53−12.37) .766 7.65 (5.64−12.54) 9.37 (5.79−15.08) .721 8.21 (4.73−21.60) 8.46 (6.71−12.01) .288 7. volume, mL, median (IQR) Location 49 (80.3) 18 (78.3) 31 (81.6) 1.000 18 (85.7) 31 (77.5) .669 19 (82.6) 30 (78.9) .987 Location 7 (%) 12 (19.7) 5 (21.7) 7 (18.4) .018 3.14.33 19 (47.5) 0.10 4.17.40 18 (47.4) .018 3.14.33 19 (47.5) 0.10 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) 0.10 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) 0.10 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) 0.10 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) 0.10 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) 0.10 4.17.40 18 (47.4) .018 3.14.33 10 (47.5) 0.10 4.17.40 18 (47.4) .018 0.000 0.0000 0.00000 0.00000 0.00000 0.00000 0.00000 0.000000	¹ T (×10 ⁹ /L), mean ±SD	231 ± 60	231 ± 54	231 ± 65	666.	223 ± 59	236 ± 62	.420	231 ± 52	232 ± 65	.965	214 ± 63	240 ± 58	.112
Baseline hematoma 8.42 (5.34–14.01) 8.02 (5.95–18.45) 8.60 (5.3–12.37) 766 7.65 (5.64–12.54) 9.37 (5.79–15.08) 7.21 8.21 (4.73–21.60) 8.46 (6.71–12.01) 288 7. volume, mL, median (IQR) volume, mL, median (IQR) 3.49 (80.3) 18 (78.3) 31 (81.6) 1.000 18 (85.7) 31 (77.5) .669 19 (82.6) 30 (78.9) .987 Location 12 (19.7) 5 (21.7) 7 (18.4) 3 (43.3) 3 (43.3) 9 (22.5) 4 (17.4) 8 (21.1) .987 sNH n (%) 22 (55) 0.10 4 (17.4) 18 (47.4) .018 3 (43.3) 3 (43.3) .018 3 (43.3) .010 4 (17.4) 18 (47.4) .018	b, g/L, mean±SD	144 ± 17	143 ± 19	156 ± 16	.543	146 ± 20	144 ± 15	.774	143 ± 17	146 ± 17	.553	147 ± 20	144 ± 15	.512
volume, mL, median (IQR) Location Deep, n (%) 49 (80.3) 18 (78.3) 31 (81.6) 1.000 18 (85.7) 31 (77.5) .669 19 (82.6) 30 (78.9) .987 Lobar, n (%) 12 (19.7) 5 (21.7) 7 (18.4) 3 (14.3) 9 (22.5) 4 (17.4) 8 (21.1) sNVH n (%) 27 (86.1) 4 (17.4) 18 (47.4) .0118 3 (14.3) 19 (47.5) 0.010 4 (17.4) 18 (47.4) .018	aseline hematoma 8	1.42 (5.84–14.01)	8.02 (5.95–18.45)	8.60 (5.53–12.37)	.766	7.65 (5.64–12.54)	9.37 (5.79–15.08)	.721	8.21 (4.73–21.60)	8.46 (6.71-12.01)	.288	7.74 (4.91–12.39)	9.37 (6.13–14.90)	.296
Location Deep, n (%) 49 (80.3) 18 (78.3) 31 (81.6) 1.000 18 (85.7) 31 (77.5) .669 19 (82.6) 30 (78.9) .987 Lobar, n (%) 12 (19.7) 5 (21.7) 7 (18.4) 3 (14.3) 9 (22.5) 4 (17.4) 8 (21.1) sNH n (%) 22 (36.1) 4 (17.4) 18 (47.4) .018 3 (14.3) 19 (47.5) 0.10 4 (17.4) 18 (47.4) .018	volume, mL, median (IQR)													
Deep, n (%) 49 (80.3) 18 (78.3) 31 (81.6) 1.000 18 (85.7) 31 (77.5) .669 19 (82.6) 30 (78.9) .987 Lobar, n (%) 12 (19.7) 5 (21.7) 7 (18.4) 3 (14.3) 9 (22.5) 4 (17.4) 8 (21.1) sNH n (%) 22 (36.1) 4 (17.4) 18 (47.4) .018 3 (14.3) 19 (47.5) 0.10 4 (17.4) 18 (47.4) .018	tion													
Lobar, n (%) 12 (19.7) 5 (21.7) 7 (18.4) 3 (14.3) 9 (22.5) 4 (17.4) 8 (21.1) sNH n (%) 22 (36.1) 4 (17.4) 18 (47.4) 018 3 (14.3) 19 (47.5) 010 4 (17.4) 18 (47.4) 018	eep, n (%)	49 (80.3)	18 (78.3)	31 (81.6)	1.000	18 (85.7)	31 (77.5)	.669	19 (82.6)	30 (78.9)	.987	16 (80.0)	33 (80.5)	1.000
sNH n (%) 22 (36.1) 4 (17.4) 18 (47.4) 018 3 (14.3) 19 (47.5) 010 4 (17.4) 18 (47.4) 018	obar, n (%)	12 (19.7)	5 (21.7)	7 (18.4)		3 (14.3)	9 (22.5)		4 (17.4)	8 (21.1)		4 (20.0)	8 (19.5)	
	VH, n (%)	22 (36.1)	4 (17.4)	18 (47.4)	.018	3 (14.3)	19 (47.5)	.010	4 (17.4)	18 (47.4)	.018	5 (25.0)	17 (41.5)	.209
CVFV, mL, median (IQR) 722 (519–993) 564 (511–753) 837 (562–1177) .036 547 (502–698) 837 (532–1142) .003 659 (511–971) 785 (542–1006) .305 .	VFV, mL, median (IQR)	722 (519–993)	564 (511–753)	837 (562–1177)	.036	547 (502–698)	837 (632–1142)	.003	659 (511–971)	785 (542–1006)	.305	558 (515–846)	790 (546–1110)	.094

Feng et al. Medicine (2018) 97:35

Table 1

5

Table 2

Multivariate analysis of perihematomal edema of spontaneous intracerebral hemorrhage.

	OR (95% CI)	Р
72-h absolute PHE		
GHb	1.130 (0.431-2.961)	.804
CVFV	0.998 (0.996-1.000)	.057
sIVH	0.315 (0.070-1.415)	.132
History of alcohol	1.370 (0.181–10.344)	.760
History of smoking	0.280 (0.038-2.055)	.211
NIHSS	1.160 (1.004–1.341)	.044
GLU	1.828 (0.823-4.061)	.139
72-h relative PHE		
sIVH	0.400 (0.099-1.625)	.200
GHb	2.300 (0.832-6.356)	.108
DM	1.622 (0.261-10.085)	.604
BMI	1.212 (0.969-1.296)	.123
12 ± 3 -Day absolute PHE		
sIVH	0.154 (0.036-0.664)	.012
CVFV	0.997 (0.995-0.999)	.006
12 ± 3 -Day relative PHE		
Glu	1.393 (0.962-2.017)	.079
DBP	0.969 (0.937-1.003)	.074
CVFV	0.998 (0.996–1.000)	.062

$$\begin{split} BMI = body \mbox{ mass index, CVFV} = cerebral venous outflow volume, DBP = diastolic blood pressure, \\ DM = diabetes mellitus, GHb: glycosylated hemoglobin, GLU = blood glucose, IQR = interquartile range, NIHSS = National Institutes of Health Stroke Scale, PHE = perihematomal edema, sIVH = secondary intraventricular hemorrhage. \end{split}$$

smoking, alcohol consumption, GHb, secondary intraventricular hemorrhage (sIVH), and CVFV in PHE at 72 hours. Only sIVH and CVFV were significantly different at 12 days in PHE. In relative PHE (rPHE), GHb, and sIVH were significantly differed at 72 hours. No significant difference was observed at 12 days in rPHE (Table 1).

3.2. Multivariate analysis

The results of univariate analyses of possible association between venous volume and PHE are shown in Table 1. Variables with P < .10 were entered into multivariate analyses. The results are shown in Table 2. The results indicated that CVFV was independently associated with late PHE (PHE at 12 ± 3 days) but not with early PHE (PHE at 72 hours) and rPHE.

4. Discussion

In this prospective cohort study conducted at the Beijing Tiantan Hospital, we found that total CVFV may be an independent predictor of smaller absolute PHE, but we did not find possible association between relative PHE and total CVFV.

This is supported by the anatomical findings of several cerebral venous blood vessels draining blood from the superficial as well as the deep cerebral venous system into the confluent sinus and from there toward the lateral sinuses and the IJVs.^[5,6,19] The reported mean total CVFVs of 4 previous studies were 656 ± 113 ,^[20] 669 ± 240 ,^[5,6] 740 ± 209 ,^[21] and 700 ± 270 mL/min.^[22] The present study showed a CVFV of 736.77 (539.69–992.71) mL/min, which was consistent with these previous results. The IJVs and VVs might be the principle outflow pathways for intracranial blood.

The mechanisms of PHE have been widely studied. According to previous studies, early stage clot retraction and cytotoxic edema promote the generation of ionic (osmotic) driving forces.^[3]

In later stage, inflammation is mainly responsible for PHE evolution.^[3] Studies have confirmed that some factors are associated with PHE. Indeed, PHE volume is directly related to the initial ICH volume at all times after the ictus.^[4] Blood pressure,^[23] hyperglycemia,^[24,25] body temperature,^[26] plasma sodium levels,^[27] and high hematocrit value on hospital admission following ICH^[28] all contribute to the volume of PHE through the mechanisms mentioned above. According to Starling's principle, transendothelial fluid transfer depends on net hydrostatic and osmotic forces.^[29] Therefore, it is easy to conclude that the factors that can increase the hydrostatic pressure may increase the volume of PHE. Abnormalities of intracranial venous drainage are bound to lead to increased intravascular hydrostatic pressure, which may lead to increased PHE. It has been reported that abnormal venous drainage is involved in the formation of malignant edema after ischemic stroke.^[19] Furthermore, PHE may result from the same processes, which cause other types of secondary brain injury, and the volume of PHE may reflect the activity of pathological mediators that underlie these processes, including cytokines, complement proteins, and matrix metalloproteinases.^[30-32] This overlap makes PHE a potential valuable marker of secondary injury that could provide a useful surrogate endpoint for experimental and clinical studies of novel therapeutic agents to prevent secondary injury after ICH.^[3]

The amount of venous drainage should be proportional to the amount of arterial inflow. In the present study, there was no difference in arterial CBF between the 2 groups of PHE, meaning that the outflow of the 2 groups is relatively equal. Therefore, we hypothesized that when ICH occurred, the hematoma itself and PHE may cause oppression on the intracranial veins, leading to the redistribution of the intracranial venous drainage. The redistribution of the drainage may lead to larger amounts of cerebral blood passing through the bypass drainage via the confluence of sinus. Nevertheless, the confluence of sinus is absent in 10% to 40% of the patients, ^[22,33,34] and the venous collaterals are often small and tortuous, which might make compensatory capacity of the bypass less efficient so that larger PHE will accumulate.^[7] Previous studies showed that elevated ICP resulting from stroke leads to alteration of flow velocities within basal veins, vein of Galen, straight sinus, and transversal sinus, supporting our hypothesis that redistribution of intracranial venous drainage occurs after ICH.^[9,35]

This study had some limitations. First the number of patients was small. Secondly, the patients had a relatively small amount of hematoma volume. Thirdly, this was a cross-sectional study and no follow-up was conducted to examine the prognosis of the patients. Finally, doubts have been raised about the use of color Doppler ultrasound to determine CVFV,^[36,37] but no study directly compared this method against more robust blood flow measurement methods in the context of PHE. Nevertheless, ultrasound is an inexpensive and easily accessible technique, and a number of studies reached valuable conclusions based on this technique.^[5,6,20–22] Additional studies are still necessary to examine the factors contributing to PHE in ICH, as well as the prognosis of the patients.

5. Conclusion

This study suggests a potential association between CVFV and PHE, although the exact mechanism still needs further study. Nevertheless, the results suggest that CVFV may participate in the process of the formation of PHE after sICH. This study might provide a novel direction for the treatment of PHE in the future.

Author contributions

Conceptualization: Hao Feng, Wen He, Xingquan Zhao.

- Data curation: Hao Feng, Zhanqiang Jin, Wen He, Xingquan Zhao.
- Formal analysis: Hao Feng, Zhanqiang Jin, Wen He, Xingquan Zhao.
- Funding acquisition: Xingquan Zhao.
- Investigation: Hao Feng, Zhanqiang Jin, Wen He, Xingquan Zhao.
- Methodology: Hao Feng, Zhanqiang Jin, Wen He, Xingquan Zhao.
- Project administration: Xingquan Zhao.
- Resources: Hao Feng, Xingquan Zhao.
- Software: Hao Feng, Xingquan Zhao.
- Supervision: Hao Feng, Zhanqiang Jin, Xingquan Zhao.
- Validation: Hao Feng, Zhanqiang Jin, Wen He, Xingquan Zhao. Visualization: Hao Feng, Xingquan Zhao.
- Writing original draft: Hao Feng, Xingquan Zhao.
- Writing review and editing: Hao Feng, Zhanqiang Jin, Wen He, Xingquan Zhao.

References

- Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol 2006;5:53–63.
- [2] Gupta M, Verma R, Parihar A, et al. Perihematomal edema as predictor of outcome in spontaneous intracerebral hemorrhage. J Neurosci Rural Pract 2014;5:48–54.
- [3] Urday S, Kimberly WT, Beslow LA, et al. Targeting secondary injury in intracerebral haemorrhage—perihaematomal oedema. Nat Rev Neurol 2015;11:111–22.
- [4] Arima H, Wang JG, Huang Y, et al. Significance of perihematomal edema in acute intracerebral hemorrhage: the INTERACT trial. Neurology 2009;73:1963–8.
- [5] Doepp F, Schreiber SJ, Von Munster T, et al. How does the blood leave the brain? A systematic ultrasound analysis of cerebral venous drainage patterns. Neuroradiology 2004;46:565–70.
- [6] Zamboni P, Sisini F, Menegatti E, et al. An ultrasound model to calculate the brain blood outflow through collateral vessels: a pilot study. BMC Neurol 2013;13:81.
- [7] Chung CP, Lin YJ, Chao AC, et al. Jugular venous hemodynamic changes with aging. Ultrasound Med Biol 2010;36:1776–82.
- [8] Monti L, Menci E, Ulivelli M, et al. Quantitative ColourDopplerSonography evaluation of cerebral venous outflow: a comparative study between patients with multiple sclerosis and controls. PLoS One 2011;6:e25012.
- [9] Stolz E, Gerriets T, Babacan SS, et al. Intracranial venous hemodynamics in patients with midline dislocation due to postischemic brain edema. Stroke 2002;33:479–85.
- [10] Rossitti S. Pathophysiology of increased cerebrospinal fluid pressure associated to brain arteriovenous malformations: the hydraulic hypothesis. Surg Neurol Int 2013;4:42.
- [11] Hao Feng HZ, Wen He, Jian Zhou, et al. Jugular venous reflux is associated with perihematomal edema after intracerebral hemorrhage. Biomed Res Int 2017;2017:7514639.
- [12] Appelros P, Terent A. Characteristics of the National Institute of Health Stroke Scale: results from a population-based stroke cohort at baseline and after one year. Cerebrovasc Dis 2004;17:21–7.
- [13] Fischer M, Ruegg S, Czaplinski A, et al. Inter-rater reliability of the Full Outline of UnResponsiveness score and the Glasgow Coma Scale in critically ill patients: a prospective observational study. Crit Care 2010;14:R64.
- [14] Zhu Y, Wang JL, He ZY, et al. Association of altered serum MicroRNAs with perihematomal edema after acute intracerebral hemorrhage. PLoS One 2015;10:e0133783.

- [15] Sun W, Pan W, Kranz PG, et al. Predictors of late neurological deterioration after spontaneous intracerebral hemorrhage. Neurocrit Care 2013;19:299–305.
- [16] Farina M, Novelli E, Pagani R. Cross-sectional area variations of internal jugular veins during supine head rotation in multiple sclerosis patients with chronic cerebrospinal venous insufficiency: a prospective diagnostic controlled study with duplex ultrasound investigation. BMC Neurol 2013;13:162.
- [17] Schoning M, Walter J, Scheel P. Estimation of cerebral blood flow through color duplex sonography of the carotid and vertebral arteries in healthy adults. Stroke 1994;25:17–22.
- [18] Scheel P, Ruge C, Petruch UR, et al. Color duplex measurement of cerebral blood flow volume in healthy adults. Stroke 2000;31:147–50.
- [19] Yu W, Rives J, Welch B, et al. Hypoplasia or occlusion of the ipsilateral cranial venous drainage is associated with early fatal edema of middle cerebral artery infarction. Stroke 2009;40:3736–9.
- [20] Muller HR. Quantitative determination of blood flow in the internal jugular vein using ultrasound [in German]. Ultraschall Med 1985;6:51–4.
- [21] Muller HR, Hinn G, Buser MW. Internal jugular venous flow measurement by means of a duplex scanner. J Ultrasound Med 1990;9:261–5.
- [22] Valdueza JM, Von Munster T, Hoffman O, et al. Postural dependency of the cerebral venous outflow. Lancet 2000;355:200–1.
- [23] Sykora M, Diedler J, Turcani P, et al. Subacute perihematomal edema in intracerebral hemorrhage is associated with impaired blood pressure regulation. J Neurol Sci 2009;284:108–12.
- [24] Qureshi AI, Palesch YY, Martin R, et al. Association of serum glucose concentrations during acute hospitalization with hematoma expansion, perihematomal edema, and three month outcome among patients with intracerebral hemorrhage. Neurocrit Care 2011;15: 428–35.
- [25] Song EC, Chu K, Jeong SW, et al. Hyperglycemia exacerbates brain edema and perihematomal cell death after intracerebral hemorrhage. Stroke 2003;34:2215–20.
- [26] Staykov D, Wagner I, Volbers B, et al. Mild prolonged hypothermia for large intracerebral hemorrhage. Neurocrit Care 2013;18:178–83.
- [27] Wagner I, Hauer EM, Staykov D, et al. Effects of continuous hypertonic saline infusion on perihemorrhagic edema evolution. Stroke 2011;42: 1540–5.
- [28] Venkatasubramanian C, Mlynash M, Finley-Caulfield A, et al. Natural history of perihematomal edema after intracerebral hemorrhage measured by serial magnetic resonance imaging. Stroke 2011;42:73–80.
- [29] Xi G, Keep RF, Hoff JT. Pathophysiology of brain edema formation. Neurosurg Clin N Am 2002;13:371–83.
- [30] Lim-Hing K, Rincon F. Secondary hematoma expansion and perihemorrhagic edema after intracerebral hemorrhage: from bench work to practical aspects. Front Neurol 2017;8:74.
- [31] Ducruet AF, Zacharia BE, Hickman ZL, et al. The complement cascade as a therapeutic target in intracerebral hemorrhage. Exp Neurol 2009;219:398–403.
- [32] Castellazzi M, Tamborino C, De Santis G, et al. Timing of serum active MMP-9 and MMP-2 levels in acute and subacute phases after spontaneous intracerebral hemorrhage. Acta Neurochir Suppl 2010;106:137–40.
- [33] Bisaria KK. Anatomic variations of venous sinuses in the region of the torcular Herophili. J Neurosurg 1985;62:90–5.
- [34] Hempel KJ, Elmohamed A. Anatomy, form variations and types of the intracranial venous system in man [in German]. Radiologe 1971;11:451–7.
- [35] Niesen WD, Rosenkranz M, Schummer W, et al. Cerebral venous flow velocity predicts poor outcome in subarachnoid hemorrhage. Stroke 2004;35:1873–8.
- [36] Purkayastha S, Sorond F. Transcranial Doppler ultrasound: technique and application. Semin Neurol 2012;32:411–20.
- [37] Zamboni P. Why current Doppler ultrasound methodology is inaccurate in assessing cerebral venous return: the alternative of the ultrasonic jugular venous pulse. Behav Neurol 2016;2016:7082856.